Código QR (código de barras bidimensional)

SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic

<b>Background and Aims</b>: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown promise in metabolic dysfunction-associated steatotic liver disease (MASLD). This large real-world study aimed to evaluate the effects of SGLT2 inhibitors on MASLD patients’ clinical outcomes and liver-related c...

ver descrição completa

Na minha lista:
Principais autores: Mohamad Suki, Ashraf Imam, Johnny Amer, Yael Milgrom, Muhammad Massarwa, Wadi Hazou, Yariv Tiram, Ofer Perzon, Yousra Sharif, Joseph Sackran, Revital Alon, Nachum Lourie, Anat Hershko Klement, Safa Shibli, Tamer Safadi, Itamar Raz, Abed Khalaileh, Rifaat Safadi
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2025-07-01
coleção:Pharmaceuticals
Assuntos:
SGLT2 inhibitors
NAFLD
MASLD
liver outcomes
cirrhosis
mortality
Acesso em linha:https://www.mdpi.com/1424-8247/18/8/1118
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados